Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 18113.50% ano a ano.
Subavaliada
O PE mais recente da empresa é -8.47, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 216.89M ações, um aumento de 18.71% em relação ao trimestre anterior.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.23.